IXHLIncannex Healthcare Ltd

Nasdaq www.incannex.com


$ 1.84 $ -0.09 (-4.87 %)    

Friday, 02-Aug-2024 15:57:23 EDT
QQQ $ 447.95 $ -10.91 (-2.37 %)
DIA $ 397.31 $ -6.10 (-1.51 %)
SPY $ 532.92 $ -10.11 (-1.86 %)
TLT $ 98.17 $ 2.97 (3.12 %)
GLD $ 225.36 $ -0.43 (-0.19 %)
$ 1.8361
$ 1.70 x 100
$ 1.84 x 199
-- - --
$ 1.65 - $ 12.68
57,050
na
29.14M
$ 1.10
nm
TBD
na
na (nm)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2024 03-31-2024 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 incannex-healthcare-files-for-offering-of-4m-common-shares-along-with-warrants-to-purchase-up-to-4m-common-shares

- SEC Filing

 fda-experts-weigh-in-on-incannexs-cannquit-o-with-feedback-on-cbd-as-treatment-for-opioid-use-disorder

Incannex Healthcare Inc., a cannabinoid and psychedelic medicine biotechnology company, announced the successful completion of ...

 psychedelic-assisted-therapy-advancements-create-a-new-horizon-for-mental-health-in-colorado

Psilocybin-assisted therapy shows promise in treating GAD. Denver trains first responders in psychedelic crisis intervention. H...

Core News & Articles

https://www.marijuanamoment.net/indiana-lawmakers-send-psilocybin-research-funding-bill-to-governor/   The Indiana legislatur...

 incannex-healthcare-tapped-treasurer-and-controller-joseph-swan-to-additional-role-of-cfo-effective-february-29-after-madhukar-bhalla-decided-to-retire

Madhukar Bhalla, Chief Financial Officer and Secretary of Incannex Healthcare Inc. (the “Company”), recently notified the Compa...

 why-bumble-shares-are-trading-lower-by-12-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results.

 whats-going-on-with-incannex-stock

Incannex said that its Phase 2 Psi-GAD1 clinical trial of psilocybin in generalized anxiety disorder met its primary endpoint o...

Core News & Articles

BYND: 105% | Beyond Meat shares are trading higher after the company reported mixed Q4 financial results. FLYW: 31% | Flywire ...

 incannex-announces-topline-results-from-phase-2-psi-gad1-clinical-trial-of-psilocybin-in-generalised-anxiety-disorder

Incannex Healthcare Inc. (NASDAQ:IXHL), (Incannex or the Company), a leading cannabinoid and psychedelic medicine biotechnology...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION